Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Flare Therapeutics Inc. manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These actions are distributed across 2 distinct examiners but are contained within 1 distinct art unit. This structure indicates that while the technical subject matter is consistent enough to stay within a single specialized group at the patent office, the individual applications are being reviewed by different people. This requires a strategy that accounts for the specific nuances of multiple examiners while operating under the general practices of one art unit.
CLARK, AMY LYNN is the busiest examiner for the company, currently responsible for 1 busiest examiner pending action. Given that there are 2 pending office actions in total, the workload is split between the 2 distinct examiners. This distribution means the company must manage separate prosecution tracks simultaneously. Success for this portfolio depends on navigating the individual preferences of these examiners, even as they work within the same technical framework of the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CLARK, AMY LYNN | 1 | 39.1% | +31.2% |
| MOU, LIYUAN | 1 | 42.9% | +59.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18387913 | PPARG INVERSE AGONISTS AND USES THEREOF | CLARK, AMY LYNN | 46d |
| 18279292 | PPARG INVERSE AGONISTS AND USES THEREOF | MOU, LIYUAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18387913 | PPARG INVERSE AGONISTS AND USES THEREOF | CLARK, AMY LYNN | 46d |
| 18279292 | PPARG INVERSE AGONISTS AND USES THEREOF | MOU, LIYUAN | — |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18387913 | PPARG INVERSE AGONISTS AND USES THEREOF | CLARK, AMY LYNN | 1628 | §102§112 | Non-Final OA | 46d | Pending | Nov 08, 2023 |
| 18279292 | PPARG INVERSE AGONISTS AND USES THEREOF | MOU, LIYUAN | 1628 | §103§112Other | Non-Final OA | — | Pending | Aug 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial